Predictors of Response to Intravitreal Anti–Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration  

Oleh:

Shah, Anjali R. ; Williams, Steven ; Baumal, Caroline R. ; Rosner, Bernard ; Duker, Jay S. ; Seddon, Johanna M.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: American Journal of Ophthalmology (keterangan: ada di ClinicalKey) vol. 163 (Mar. 2016), page 154-166.
Topik: Visual Acuity; VA; Optical Coherence Tomography; OCT
Fulltext: A12 v163 p154 kelik2016.pdf (350.19KB)

Ketersediaan

Perpustakaan FK Nomor Panggil: A12.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Purpose: To identify factors that influence visual and anatomic response to treatment with intravitreal anti–vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (AMD). Design: Observational cohort study. Methods: Seventy-two patients were included in this study. Best-corrected Snellen visual acuity (VA) and central foveal thickness measured on optical coherence tomography (OCT) at time of treatment and post-treatment follow-up visits were recorded. Associations between demographic, behavioral, and genetic risk factors and the 2 outcomes were analyzed using mixed-effects linear regression models. Two loci in complement factor H (CFH) were included in a risk score to determine the association between CFH risk and improvement in VA and central foveal thickness. Results: There was a small improvement in VA following anti-VEGF treatment (mean: 3.7 ± 3.0 letters), which was not statistically significant. Significant improvement in VA was observed for the nonrisk CFH Y402H genotype (P < .001) and for a low CFH risk score (P = .019). Regarding the outcome of change in central foveal thickness, improvement was noted in all genotype groups, but reduction after treatment was significantly higher in the lowCFH risk score group (P = .033). A significant improvement in mean VA was seen among smokers (P < .001), but this relationship was not observed for central foveal thickness. Conclusion: After anti-VEGF therapy, significant improvement in VA was observed for low-risk CFH genotypes and subjects with a low risk score. There was a statistically significant reduction in central foveal thickness overall, and subjects with a low CFH risk score improved more than the high-risk group.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali